SOUTH SAN FRANCISCO, California, March 10 -- Genentech, a member of Roche Group, issued the following news release on March 8, 2026:

* * *

Genentech Provides Update on Phase III persevErA Study in ER-Positive Advanced Breast Cancer

* persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed

* Giredestrant plus palbociclib wa . . .

Click here for more information about our products